GSC
MITO

Ground Swell Capital’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Ground Swell Capital’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,927
Closed -$16K – 122
2021
Q4 		$16K Buy
+18,927
New +$19.7K 0.09% 61

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Ground Swell Capital's MITO Position: Q1 2022 in Review

Ground Swell Capital sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q1 2022, closing a stake of 18,927 shares — an estimated $16K sold.

Ground Swell Capital first reported a position in MITO in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 13 funds tracked by Wall St. Rank hold MITO as of Q1 2022.

  • Ground Swell Capital reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q1 2022 after selling out during the quarter.
  • Ground Swell Capital sold 18,927 Stealth BioTherapeutics Corp. ADS shares in Q1 2022, an estimated $16K.
  • Ground Swell Capital first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2021 and held it in 1 quarter.
  • Ground Swell Capital's Stealth BioTherapeutics Corp. ADS position peaked at $16K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q1 2022.

Based on Ground Swell Capital's 13F filing for Q1 2022, filed 10 May 2022.